Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19

清华大学、深圳第三人民医院和布里生物科技建立合作,发展 COVID-19抗体

2020-04-01 14:00:17 BioSpace

本文共2041个字,阅读需6分钟

Multiple highly potent, neutralizing antibodies already identified from convalesced patients First-in-human trials planned for third quarter this year BEIJING & DURHAM, N.C.--(BUSINESS WIRE)-- Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences (“Brii Bio”) today announced a partnership and license agreement to discover, develop, manufacture and commercialize fully human neutralizing monoclonal antibodies to address the global pandemic of COVID-19. Researchers in the laboratories of Professor Linqi Zhang at Tsinghua University and Professor Zheng Zhang at 3rd People’s Hospital of Shenzhen have identified multiple diverse and potent neutralizing monoclonal antibodies with therapeutic potential against SARS CoV-2 that have been characterized from patients in China who have recovered from COVID-19. Tsinghua and 3rd People’s Hospital of Shenzhen published the results of their discovery research in the preprint server BioRxiv. Based on this research, the university and hospital, together with Brii Bio, intend to advance multiple candidates for prophylactic and therapeutic intervention. “We have been able to move very quickly by virtue of our proximity to the initial outbreak and our expertise from prior research in SARS and MERS,” said Professor Linqi Zhang, Tsinghua University. “Our investigators have worked day and night since the beginning of the outbreak. With Brii Bio joining and the dedicated focus afforded by this new venture, we expect to accelerate our development efforts with the shared goal of bringing forward an effective therapy to benefit people around the world affected by this pandemic.” “Since the beginning of the outbreak, our hospital had responded urgently to focus on searching for monoclonal antibodies against COVID-19. Our teams worked extremely hard and isolated hundreds of monoclonal antibodies early on through single B-cell sorting and rapid sequencing, thereby laying the foundation for further optimization of these neutralizing antibodies,” commented Professor Zheng Zhang, 3rd People’s Hospital of Shenzhen. “Our partnership with Tsinghua and Brii Bio will accelerate the development of these neutralizing antibodies to the clinic and may help to slow down the spread of the COVID-19 pandemic.” “Our collaboration with Tsinghua University and 3rd People’s Hospital of Shenzhen perfectly aligns with Brii Bio’s mission to make significant contributions to public health throughout the world,” said Zhi Hong, Ph.D., CEO of Brii Bio. “With a shared vision, the collaboration marries the abilities of Tsinghua University and 3rd People’s Hospital of Shenzhen to rapidly discover antibodies against SARS-CoV-2 with Brii Bio’s development expertise in infectious diseases to create an innovative collaboration model and bring the best people together to address the current public health challenge and ones to come.” Through this effort, Tsinghua, 3rd People’s Hospital of Shenzhen and Brii Bio seek to achieve an accelerated timeline of six months from the selection of a lead development candidate to the first-in-human clinical trials, with the potential for additional timeline acceleration. Tsinghua and collaborators at 3rd People’s Hospital of Shenzhen will provide capabilities and researchers to ensure all necessary testing, screening, virologic, biochemical and cell culture characterizations. Brii Bio will provide development expertise, antibody optimization, intellectual protection, project management, CDMO management, and clinical and regulatory oversight. About Tsinghua University Tsinghua University was established in 1911 under the name “Tsing Hua Imperial College.” Tsinghua is an important hub for scientific research and talent cultivation. For more than 100 years with the goal of leading global fundamental research and serving core national development strategies, Tsinghua University is dedicated to optimizing scientific discipline and academic settings and promoting innovation capabilities for top-notch research outcomes. About Shenzhen No.3 People’s Hospital National Clinical Research Center for Infectious Diseases / Third People's Hospital of Shenzhen (Second Affiliated Hospital of Southern University of Science and Technology) was founded in 1985, formerly known as "Shenzhen Donghu Hospital", which was then renamed in 2008. The hospital is a modern Class 3A research hospital founded by the Shenzhen Municipal Government under the “comprehensive general hospital with strong specialty focus” guiding principle. The hospital is mainly responsible for the prevention and control of infectious diseases and major epidemics in Shenzhen and surrounding areas, and provides comprehensive general medical services. It is the most comprehensive and largest infectious disease general hospital in southern China. The Third People's Hospital of Shenzhen is committed to the clinical diagnosis, treatment and research of major infectious diseases with a long history, with extensive experience in major epidemics such as SARS, H5N1 and H9N1 avian influenza, MERS, and SAR-CoV-2, where the hospital had undertaken major clinical diagnosis and treatment tasks, and established systematic systems in diagnosis, treatment and research. About Brii Biosciences Brii Biosciences (Brii Bio) is committed to serving patients' needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People's Republic of China and the United States, the company is poised to serve as a bridge to carry transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the health and wellbeing of patients around the world. The company is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and other illnesses. For more information, visit www.briibio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005114/en/ Tsinghua University Liang Xu xliang@tsinghua.edu.cn Brii Biosciences Lindy Devereux lindy@scientpr.com +1-646-515-5730 Source: Brii Biosciences View this news release online at: http://www.businesswire.com/news/home/20200331005114/en
已从康复病人身上发现的多重高效力中和抗体 今年第三季度计划进行首次人体试验 北京& DURHAM , N.C .---( Business SINESS WIRE )----清华大学、深圳第三人民医院和布里生物科学公司( Brii Biosciences )今天宣布了一项合作伙伴关系和许可协议,以发现、开发、制造和商业化完全人类中和的单克隆抗体,以应对全球流行的 COVID-19。 清华大学张林奇教授和深圳第三人民医院张郑教授实验室的研究人员已经确定了多个具有治疗 SARS CoV-2潜力的多种不同且有效的中和单克隆抗体,这些抗体的特点是来自于从 COVID-19中恢复过来的中国患者。清华和深圳第三人民医院在印前服务器 BioRxiv 上公布了他们的发现研究结果。基于这项研究,大学和医院,连同布里生物,打算推进多个候选人的预防和治疗干预。 清华大学张林琦教授表示:“由于我们接近首次爆发疫情,而且我们以前在 SARS 和 MERS 方面的研究具有专业知识,因此我们能够迅速采取行动。”“自疫情爆发以来,我们的调查人员每天晚上都在工作。随着 Brii Bio 的加入,以及这个新项目带来的专注,我们希望加快我们的发展努力,共同目标是提出一种有效的治疗方法,使受这场大流行影响的全世界人民受益。” “自从爆发以来,我们的医院已经紧急作出反应,致力于寻找抗 COVID-19的单克隆抗体。深圳第三人民医院郑章教授表示:“我们的团队通过单细胞分选和快速测序,非常努力地分离了数百个单克隆抗体,为进一步优化这些中和抗体奠定了基础。”“我们与清华和布里生物的合作将加快开发这些中和抗体的临床,并可能有助于减缓 COVID-19大流行的传播。” “我们与清华大学和深圳第三人民医院的合作,完全符合百益生物对全球公共卫生做出重大贡献的使命,”百益生物首席执行官智宏博士表示。“有着共同的愿景,这一合作关系到清华大学和深圳第三人民医院迅速发现 SARS-CoV-2抗体的能力,以及 Brii Bio 在传染病领域的发展专长,以创建创新的合作模式,将最优秀的人聚集在一起,应对当前的公共卫生挑战和未来的挑战。” 通过这一努力,清华、深圳第三人民医院和百益生物寻求实现从选择一名首席开发候选人到首次进行人体临床试验的六个月的加速时间表,并有可能进一步加快时间表。清华和深圳第三人民医院的合作者将提供能力和研究人员,以确保所有必要的测试、筛选、病毒学、生化和细胞培养特性。Brii 生物将提供开发专业知识、抗体优化、知识保护、项目管理、 CDMO 管理、临床和法规监督。 关于清华大学 清华大学成立于1911年,名为“清华帝国学院”。清华是科学研究和人才培养的重要中心。一百多年来,清华大学以引领全球基础研究、服务国家核心发展战略为目标,致力于优化科学学科和学术环境,提升一流研究成果的创新能力。 关于深圳市第三人民医院 国家传染病临床研究中心/深圳市第三人民医院(南方科技大学第二附属医院)成立于1985年,前身为“深圳东湖医院”,2008年更名。医院是深圳市政府在“专业重点强的综合性综合医院”指导原则下创办的现代化3A 级研究医院。医院主要负责深圳及周边地区传染病、重大疫情的防控工作,提供全面的综合医疗服务。是华南地区最全面、规模最大的传染病综合医院。深圳第三人民医院致力于历史悠久的重大传染病的临床诊断、治疗和研究,在 SARS 、 H5N1和 H9N1禽流感、 MERS 、 SAR-CoV-2等重大流行疾病领域具有丰富的经验,医院承担了重大的临床诊断和治疗任务,建立了系统的诊断、治疗和研究体系。 关于布里生物科学 Brii Biosciences ( Brii Biosciences , Brii Biosciences )致力于通过合作伙伴关系、一流的研发以及数字化和数据洞察的颠覆性应用,加快突破性药物的开发和交付,满足患者需求,改善公众健康。公司在中华人民共和国和美国开展业务,将作为向患者输送变革性药物的桥梁,帮助我们的合作伙伴创造显著增长,并建立创新引擎,帮助改善全球患者的健康和福祉。该公司正在开发治疗具有重大公共卫生负担的疾病,包括传染病、肝病和其他疾病。有关详细信息,请访问 www.briibio.com 。 查看 businesswire 上的源代码。com : https://www.businesswire.com/news/home/2020031005114/en/ 清华大学 梁旭 xlian @ Tsinghua.edu.cn Brii Biosciences Lindy Devereux lindy @ scientpr.com +1-646-515-5730 资料来源: Brii Biosciences 在线查看本新闻稿,网址为: http://www.businesswire.com/news/home/20203100514/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文